Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (4 ops.)
Latest filing published 23 Aug 2022 for bluebird bio, Inc., €78k. Read the official filing
Filing timeline
BuySaleJason Cole
Insider track record
Disclosed buys
0
Disclosed sells
4
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Jason Cole: trading record in brief
Jason Cole, listed as senior executive, appears in our data through filings on bluebird bio, Inc. shares, published by SEC (Form 4). In total, 7 filings cover trades dated from 3 May 2021 to 19 August 2022.
Sales make up the whole of the open-market record (4 sales, €124k). Other entries cover 2 share grants. In 2022 alone, the filings show no purchases and 3 sales.
On 23 August 2022 came the latest disclosure, an open-market sale for €78k in bluebird bio, Inc. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Jason Cole
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations7 total
14,194 shares@ US$5.528656.8% of flowCommon StockSEC:0001562180-22-006290:0
7,448 shares@ US$4.391423.3% of flowCommon StockSEC:0001562180-22-005941:0
25,000 shares0Common StockSEC:0001562180-22-001083:0
1,584 shares@ US$9.402248.3% of flowCommon StockSEC:0001562180-22-000443:0
1,539 shares0Common StockSEC:0001628280-21-023652:0
32,266 shares0Common StockSEC:0001562180-21-005171:0
38 shares@ US$30.15110.8% of flowCommon StockSEC:0001562180-21-003230:0
7 of 7 declarations
